Mitomycin C is an antitumour antibiotic used as a chemotherapy medicine. It works as a potent DNA crosslinker: once activated inside the body it forms a reactive mitosene that alkylates guanine bases at specific DNA sequences, blocking the copying of DNA into RNA and stopping protein synthesis, which takes away a cancer cell's ability to multiply. It treats upper gastrointestinal, anal and breast cancers by intravenous injection, and is also used topically in eye surgery and instilled directly into the bladder for bladder cancer. Japanese scientists discovered it in 1955 from the soil bacterium Streptomyces caespitosus, and researchers at Kyowa Hakko Kogyo isolated the purified compound as purple crystals in 1956.
Facts
Classification
Approval Status ATC ClassSourced to the subject's own accountL: Antineoplastic and Immunomodulating Agents 2 Route of Administration Route of Administration First Approved / Isolated Year Connections
Sources
1. Mitomycin C (Wikipedia)
2. Anatomical Therapeutic Chemical Classification System (Wikipedia)
WikipediaFirst-level anatomical group codes, Code LQuote, First-level anatomical group codes, Code L
Antineoplastic and immunomodulating agents
View the Source 3. Mitomycin C (Wikipedia)
WikipediaInfobox drug, routes_of_administrationQuote, Infobox drug, routes_of_administration
Intravenous, topical, intravesical
View the Source 4. Federal Register: Determination That MUTAMYCIN (Mitomycin) Was Not Withdrawn for Safety Reasons
Approval historyQuote, Approval history
Mutamycin (mitomycin) injectable was initially approved on May 28, 1974
View the Source Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.